Amivantamab-Chemotherapy Shows Promise for EGFR-Mutant Lung Cancer

New results from the phase 3 PAPILLON clinical trial demonstrate that amivantamab combined with carboplatin-pemetrexed chemotherapy provides the longest overall survival reported to date for patients with advanced non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations. This first-line treatment approach significantly outperformed standard chemotherapy alone in previously untreated patients. The findings were unveiled at the 2026 International Association for the Study of Lung Cancer World Conference, offering new hope for individuals diagnosed with this challenging genetic variant of lung cancer. This advancement could reshape treatment guidelines for EGFR-mutant lung cancer patients in Puerto Rico and globally.